Next US FDA Generics Leader Must Have ‘Frank Conversations’ With Colleagues, Industry, Former OGD Director Says

Susan Rosencrance, who helped negotiate GDUFA III, will take over as acting director of the Office of Generic Drugs following Sally Choe’s departure on 8 October. Former OGD head Uhl says the director needs to be the ‘number one advocate for the generic drug program inside the agency.’

Leadership change
Rosencrance is a 30-year veteran of the FDA, including 24 years spent working in OGD. • Source: Shutterstock

More from Generics

More from Biosimilars & Generics